Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Update re Proposed Fundraise

28 Oct 2025 17:32

RNS Number : 1868F
Belluscura PLC
28 October 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

28 October 2025

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura LLC Update

 

Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, announced on 12 September 2025 that having previously terminated discussions with Omaha Value, Inc. and AI Ventures, Inc (together the "Omaha Investor Group") regarding a proposal to refinance the Company, those discussions had been revived in order to consider a revised and detailed proposition from the Omaha Investor Group. The Company remains in protracted discussions with the Omaha Investor Group but funding has not yet been confirmed and there can be no certainty that the funding will be secured.

 

In the meantime, given the rate of progress on the proposed refinancing, Sallyport Commercial Finance ("Sallyport"), the secured funder of the Company's wholly-owned US trading subsidiary Belluscura LLC, has foreclosed on the facility and the Company's directors have been notified of the disposal of the collateralised assets of Belluscura LLC to a third party, which is unconnected to the Company or the directors. Those assets comprised principally various items of physical stock, intellectual property and various customer and distributor details and databases. The sale did not include the intellectual property licensed from Separation Design Group, LLC, which comprises the principal IP behind the Company's portable oxygen concentrators. Sallyport has now been repaid in full and further accounts receivable will now flow into Belluscura LLC. 

 

Given the scale of Belluscura LLC's remaining liabilities the Board anticipates that without the proposed refinancing from the Omaha Investor Group, Belluscura LLC will be required to file for Chapter 7 under the U.S. Bankruptcy Code. The bankruptcy of Belluscura LLC would constitute an event of default under certain of the Company's and Belluscura LLC's existing contractual arrangements including, without limitation, the existing convertible loan notes issued by the Company.

 

A further announcement will be made in due course.

 

 

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Paul Tuson, Chairman

 

SPARK Advisory Partners Limited

Nominated Adviser

Neil Baldwin

Tel: +44 (0)20 3368 3550

 

Dowgate Capital Limited

Joint Broker

Russell Cook / Daniel Ingram

Tel: +44 (0)20 3903 7715

 

Allenby Capital Limited

Joint Broker

Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)

 

Tel: +44 (0)20 3328 5656

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPKFBBOBDDFKB
Date   Source Headline
2nd Dec 20257:00 amRNSCancellation - Belluscura plc
5th Nov 20259:47 amRNSIntention to appoint Administrator Update
31st Oct 202512:15 pmRNSIntention to appoint Administrator
30th Oct 202511:30 amRNSReplacement Statement re US Subsidiary Update
30th Oct 202510:38 amRNSStatement re US Subsidiary Chapter 7 Update
28th Oct 20255:32 pmRNSUpdate re Proposed Fundraise
22nd Sep 20257:00 amRNSDirectorate Change
12th Sep 20254:57 pmRNSBoard Appointment
26th Aug 20256:00 pmRNSSuspended Companies Notice - Deletion
11th Aug 20257:00 amRNSUpdate re Strategic Review and Proposed Fundraise
1st Jul 20257:30 amRNSSuspension - Belluscura PLC
30th Jun 20257:00 amRNSStrategic Review Update and Proposed Fundraising
19th Jun 202511:07 amRNSHolding(s) in Company - Replacement
18th Jun 20255:01 pmRNSHolding(s) in Company
13th May 202512:54 pmRNSResponse to Share Price Movement
9th May 20257:00 amRNSTrading update & commencement of strategic review
16th Apr 20257:00 amRNSTrading Update and Directorate Change
8th Apr 20252:45 pmRNSHolding(s) in Company
8th Apr 20257:00 amRNSStatement re proposed imposition of Tariffs
27th Mar 20253:15 pmRNSHolding(s) in Company
10th Mar 20255:49 pmRNSHolding(s) in Company
6th Mar 20254:21 pmRNSHolding(s) in Company
6th Mar 20251:08 pmRNSHolding(s) in Company
5th Mar 20252:21 pmRNSHolding(s) in Company
4th Mar 20253:50 pmRNSHolding(s) in Company
28th Feb 20253:44 pmRNSReplacement: Result of General Meeting
28th Feb 20251:32 pmRNSResult of General Meeting
13th Feb 20257:30 amRNSHolding(s) in Company
12th Feb 20257:00 amRNSPosting of Circular and Notice of General Meeting
11th Feb 20257:00 amRNSResult of oversubscribed WRAP Retail Offer
7th Feb 20257:05 amRNSLaunch of WRAP Retail Offer
7th Feb 20257:00 amRNSResult of Share Placing
6th Feb 20255:22 pmRNSProposed Share Placing
5th Feb 20257:30 amRNSRule 19.6(c) confirmation of post-offer intentions
20th Dec 20243:20 pmRNSAppointment of Allenby Capital as Joint Broker
11th Dec 20243:21 pmRNSHolding(s) in Company
22nd Nov 20247:00 amRNSNew $4million Credit Facility
12th Nov 20244:34 pmRNSHolding(s) in Company
28th Oct 20247:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
13th Sep 20241:37 pmRNSHolding(s) in Company
12th Sep 20243:05 pmRNSHolding(s) in Company
27th Aug 20242:17 pmRNSResult of General Meeting
27th Aug 20247:00 amRNSAGM Trading Statement
2nd Aug 20247:00 amRNSNotice of AGM
31st Jul 20241:11 pmRNSTotal Voting Rights
19th Jul 202410:36 amRNSDirector/PDMR Shareholding
11th Jul 202411:30 amRNSDirectorate Change
8th Jul 202412:45 pmRNSResult of General Meeting
4th Jul 20241:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.